In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.
The pharmaceutical industry is in a wait-and-see mode as the UK tries to come up with a new Brexit plan that will mend internal division in the UK while still satisfying the EU. What is the impact on supply and pharma regulation?
Brexit: where it...
Norman Sharpless, MD, became Acting Commissioner of Food and Drugs for the US Food and Drug Administration (FDA) in early April after taking the helm from FDA Commissioner Scott Gottlieb, who stepped down for personal reasons. With a new executive...
Some members of Congress as well as Presidential candidates have proposed establishing a single-payer healthcare system in the US. A recent analysis by the Congressional Budget Office (CBO) examines the cost and benefits, including the impact for...
Pricing pressure and underperformance in the US generics market led several of the major generic-drug companies in 2018 to re-evaluate their businesses and put forth new strategies. Some companies say they are seeing signs of stabilization, but...
The European Parliament voted last month to allow manufacturing waivers to supplementary protection certificates (SPCs), a move supported by generics and biosimilars producers and manufacturers of active pharmaceutical ingredients (APIs), but...
Clarivate Analytics’ Cortellis Drugs to Watch 2019 Report identifies seven drugs that are set to enter the market in 2019 and achieve blockbuster status by 2023. Which drugs are projected to make the mark?
Examing the potential blockbusters
In...
Biologics' share in the industry’s pipeline and in the global pharmaceutical market is increasing, so what are the key issues shaping the current and future direction of biomanufacturing? Industry experts share their perspectives.
Gaining an...
Cell and gene therapies are a niche product area, but with manufacturing capacity limited, several companies, including Novartis, Roche, Catalent, and Thermo Fisher, are getting into the market with multi-billion-dollar deals.
Inside the cell and...
What have been other important developments from CDMOs, CMOs, and other suppliers thus far in 2019? A look at DCAT member companies making the news.
Here are the highlights of announcements from contract development and manufacturing organizations...
What is on the minds of leading pharmaceutical industry executives? The DCAT Week ’19 education programs featured insight on key issues impacting the pharmaceutical industry, manufacturing, and supply.
Changes in drug development and the impact on...
